Navigation Links
Questcor Reports First Quarter Financial Results
Date:4/30/2013

ales

135,12995,968Cost of sales (exclusive of amortization of purchased technology)

16,1895,520Gross profit

118,94090,448Operating expenses:Selling and marketing

35,46121,716General and administrative

12,5485,442Research and development

10,7935,665Depreciation and amortization

1,070290Impairment of purchased technology

719—Total operating expenses

60,59133,113Income from operations

58,34957,335Interest and other (expense) income, net

(342)216Foreign currency transaction loss

(488)—Income before income taxes

57,51957,551Income tax expense

18,45519,008Net income

$

39,064$

38,543Change in unrealized gains or losses on available-for-sale securities, net of related tax effects and changes in foreign currency translation adjustments.

(1,194)91Comprehensive income

$

37,870$

38,634Net income per share:Basic

$

0.68$

0.61Diluted

$

0.65$

0.58Shares used in computing net income per share:Basic

57,85763,491Diluted

60,27166,471Dividends declared per share of common stock

$

0.25$

— Reconciliation of Non-GAAP Adjusted FinancialThree Months EndedMarch 31,20132012Adjusted net income

$
45,832

$
40,610Share-based compensation expense (1)

(4,162)

(1,550)Depreciation and amortization expense (2)

(1,447)

(196)Interest expense associated with contingent consideration (3)

(196)

0Compensation expense associated with BV Trust (4)

(146)

0Foreign currency transaction loss (5)

(330)

0Tax adjustments (6)

0

(321)Impairment of purchased technology (7)

(487)

-Net income - GAAP

$
39,064

$
38,543Adjusted net income per share
'/>"/>

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Questcor to Report First Quarter Results on April 30, 2013
2. Questcor Reports Fourth Quarter and Full Year 2012 Results
3. Questcor to Report Fourth Quarter and Full Year 2012 Financial Results on February 26, 2013
4. Questcor Pharmaceuticals Appoints Michael Aldridge to the Position of Senior Vice President, Corporate Strategic Development
5. Questcor Pharmaceuticals Accelerates Cash Dividend; Payment Date Set for December 21, 2012
6. Harwood Feffer LLP Announces Investigation of Questcor Pharmaceuticals, Inc.
7. Questcor to Conduct Conference Call to Discuss Reimbursement Process
8. Questcor Comments on Insurance Policy Bulletin
9. Questcor and The Myositis Association Team Up To Support Research and Educational Initiatives in Polymyositis and Dermatomyositis
10. Questcor Pharmaceuticals to Present at Investor Conferences in September
11. Questcor Reports Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... Echo Therapeutics, Inc. (NASDAQ: ECTE ... recent unauthorized public statements relating to Echo that have ... Shepard M. Goldberg, two members of the Echo Board ... the Echo Board by an affiliate of Platinum Management ... in numerous unauthorized public communications targeted at Echo stockholders, ...
(Date:10/2/2014)... 2014  Eli Lilly and Company (NYSE: LLY)  ... -- being studied for the treatment of systemic ... due to insufficient efficacy in two pivotal Phase ... safety concerns. ­­­­ In the ILLUMINATE ... endpoint, at either dose studied, of statistically significant ...
(Date:10/2/2014)... plc (NYSE: PRGO ; TASE), a public limited ... (the " Company "), today announced the expiration of ... of its new 1.30% Senior Notes due 2016 (the " ... Notes due 2018 (the " 2018 Exchange Notes "), $800,000,000 ... 2023 Exchange Notes ") and $400,000,000 of its new 5.30% ...
Breaking Medicine Technology:Echo Therapeutics Comments On Unauthorized Public Statements By Michael M. Goldberg, M.D. And Shepard M. Goldberg 2Echo Therapeutics Comments On Unauthorized Public Statements By Michael M. Goldberg, M.D. And Shepard M. Goldberg 3Echo Therapeutics Comments On Unauthorized Public Statements By Michael M. Goldberg, M.D. And Shepard M. Goldberg 4Lilly to Discontinue Development of Tabalumab Based on Efficacy Results in Phase 3 Lupus Studies 2Lilly to Discontinue Development of Tabalumab Based on Efficacy Results in Phase 3 Lupus Studies 3Perrigo Company plc Announces Expiration Of Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023, 5.30% Senior Notes Due 2043 2Perrigo Company plc Announces Expiration Of Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023, 5.30% Senior Notes Due 2043 3Perrigo Company plc Announces Expiration Of Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023, 5.30% Senior Notes Due 2043 4
... 5, 2007 - Australian,biotechnology company Avexa (ASX:AVX) announced ... which,represents the first 24 week segment of its ... open-label section of the,trial (weeks 24 to 48) ... day as part of their daily treatment regime.,The ...
... Primary endpoint achieved -- , LAINATE, Italy - ... today positive preliminary results from its,phase II/III study ... is a broad spectrum, semi-synthetic,antibiotic that is not ... of Cosmo's MMX(tm) technology, which delivers the active,ingredient ...
Cached Medicine Technology:Avexa's Apricitabine Clinical Trial Update 2Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III,Data with Rifamycin MMX in Infectious Diarrhea 2
(Date:10/2/2014)... PA (PRWEB) October 02, 2014 ... of the 2014 BIG Awards for Business program. ... and organizations with a proprietary judging process scored ... around the globe. , “The winners this year ... Russ Fordyce, Managing Director of the Business Intelligence ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, ... a neurotic personality style and prolonged stress may have ... suggests. Tracking 800 women over nearly four decades, ... jealous and moody -- which they defined as neurotic ... of developing Alzheimer,s compared to women scoring lowest in ...
(Date:10/2/2014)... By Steven Reinberg ... -- Living close to a major highway may raise your ... Among more than 5,000 postmenopausal women, those who lived within ... greater risk of developing high blood pressure than women living ... "The results of this study highlight the importance of our ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, 2014 (HealthDay ... have a total of 500 confirmed cases of Enterovirus D68, ... since the summer, U.S. health officials reported Wednesday. Four ... but it,s not clear what role -- if any -- ... officials are also trying to determine if the virus is ...
(Date:10/1/2014)... team of scientists has shown that more than 80 ... existing drugs. , The study found that medicines called ... a genetic mutation that is present in more than ... are currently used, or are in clinical trials, for ... disorders. , Bowel cancer is the second-most common cancer ...
Breaking Medicine News(10 mins):Health News:Innovation Dominant Theme among 2014 Big Awards for Business Winners and Finalists 2Health News:Jealous, Moody Women May Face Higher Alzheimer's Risk, Study Says 2Health News:Jealous, Moody Women May Face Higher Alzheimer's Risk, Study Says 3Health News:Living Near a Highway May Be Bad for Your Blood Pressure 2Health News:Living Near a Highway May Be Bad for Your Blood Pressure 3Health News:42 States Reporting Respiratory Virus That Targets Kids 2Health News:42 States Reporting Respiratory Virus That Targets Kids 3Health News:Eighty percent of bowel cancers halted with existing medicines 2
... movement, study finds, , , WEDNESDAY, Feb. 18 (HealthDay News) ... of their impaired physical abilities, even if it,s been ... paralysis on the right side after a stroke were ... hold and move objects after they participated in robot-assisted ...
... finds misdiagnosis risk goes up as age goes down , , ... of numbness at a Detroit emergency room was discharged after ... woman with sharp pain in her left eye and loss ... doctors that she had a migraine. , And a 29-year-old ...
... health complications , during National Eating Disorders Awareness WeekLISLE, ... wants to call attention to the dangers surrounding ... treatment during National Eating Disorders Awareness Week -- Feb. ... concern and can cause a variety of oral health ...
... this week,s Journal of the American Medical,Association ... of Bioinformatics at the National Institute of Statistical Sciences, ... statistical limitations of a study,claiming that bisphenol A is ... liver,enzyme levels. The earlier study, published in JAMA ...
... 18 Specialty Underwriters,Alliance, Inc. (Nasdaq: SUAI ... on Friday, March 6, 2009 at 11:00 a.m. Eastern ... year end results for 2008. Detailed,financial information will ... 2009. , Interested parties may ...
... Feb. 18 Monthly menstrual cycles ... can include cramps, headaches and bloating. With more ... dysmenorrhea, regular vomiting also is a symptom. This ... to a study in the November/December 2008 issue ...
Cached Medicine News:Health News:Working With Robots May Help After a Stroke 2Health News:ER Less Likely to Diagnose Stroke in Younger Folks 2Health News:ER Less Likely to Diagnose Stroke in Younger Folks 3Health News:Dentists Often First to Spot Eating Disorders in Patients 2Health News:Dentists Often First to Spot Eating Disorders in Patients 3Health News:Specialty Underwriters' Alliance, Inc. Announces Fourth Quarter and Year End 2008 Conference Call 2Health News:Women Only: Cramps, Bloating and Now, Tooth Erosion? 2Health News:Women Only: Cramps, Bloating and Now, Tooth Erosion? 3
Diamond Point Bone Probe with Ortho-Grip® silicone rubber palm style handles and,stainless steel impactor caps....
The AV Plus DX pacing lead is designed for use with the St. Jude Medical Affinity VDR pulse generator. This single-lead pacing system provides reliable pacing therapy with the added benefits of AV sy...
Steroid eluting pacemaker leads...
The Guidant Fineline II Sterox is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
Medicine Products: